HPGC Renmintongtai Pharmaceutical Corporation
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Harbin Pharmaceutical Group Renmin Tongtai Pharmaceutical Co., Ltd. was renamed from Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. after a major asset restructuring in April 2015. The company's securities code is "600829" and the securities abbreviation is "Renmin Tongtai". The controlling shareholder of the company is Harbin Pharmaceutical Group Co., Ltd. The company currently has two wholly-owned subsidiaries, Harbin Pharmaceutical Group Pharmaceutical Co., Ltd. and Harbin Pharmaceutical Group Sanjing Hospital Investment Management Co., Ltd., mainly engaged in pharmaceutical wholesale and retail business. It is a well-known pharmaceutical circulation enterprise in China and a leading enterprise in pharmaceutical commerce in Heilongjiang Province. The company has established a leading pharmaceutical business brand with advanced business philosophy and professional high-quality services, which is characterized by "business ethics and honest service". It is in a leading position in various rankings of pharmaceutical business nationwide. The company's wholesale business ranked 27th in the national drug distribution industry in 2018; The company's retail business ranked 24th among the top 100 pharmaceutical retail enterprises in China in 2018. In March 2016, the company was awarded the "Best Management Innovation Award in China's Drug Distribution Industry during the 12th Five Year Plan". The company currently operates over 10000 varieties and specifications, and has established good cooperative relationships with over 2000 suppliers. The company's subsidiary Renmin Tongtai Pharmaceutical Chain Store has nearly 350 chain stores in Heilongjiang Province. Among them, there are 260 directly operated chain stores in Harbin and 90 directly operated chain stores outside the city, with an annual revenue of 1 billion yuan. They have a "dominant" position in the retail market of Heilong Province. In 2012, the company seized the opportunity of pharmaceutical e-commerce and established the first online pharmacy in Heilongjiang Province - "People's Tongtai Health Network", officially entering the field of pharmaceutical e-commerce. Developed the "Harbin Pharmaceutical People's Tongtai APP" to support online drug purchases with social security cards, achieving the first full platform in China to support online payment with social security cards. In 2019, Renmin Tongtai chain stores settled in "Meituan", "Hungry", and "JD Home", achieving integration of online and offline sales, gradually enhancing the brand's online influence and promoting sales growth on the platform. In 2019, in compliance with industry policies, a remote prescription review center was established to provide security for prescription drug sales. At the same time, practicing pharmacists provided online medication consultation and guidance to all customers, improving the professionalism of services and optimizing customer service experience. At the same time, we have created four DTP professional pharmacies that meet national standard certification. The company's wholesale business has a sound and strong sales network, covering terminal medical services throughout the province; We have established a stable and fast commercial distribution channel that radiates throughout the province, with strong market allocation capabilities, and have expanded to markets outside Jilin, Inner Mongolia, and other provinces. At present, wholesale enterprises have over 3600 sales outlets, including over 1000 medical institutions, over 1900 third-party terminals, and nearly 700 commercial customers. The market coverage rate of tertiary and above hospitals is over 95%, and the sales revenue of each tertiary and first-class hospital ranks first; Hospitals at or above the second level have a market coverage rate of over 90%, with strong network coverage and market control capabilities. Two large wholesale enterprises under the company, the Pharmaceutical Branch and the New and Special Medicines Branch, jointly occupy the leading position in wholesale business within the province. The company has established stable cooperative relationships with joint ventures and top 100 domestic enterprises. In recent years, it has transformed and upgraded to an "active marketing" enterprise, providing full supply chain extension services to upstream and downstream customers, further strengthening cooperation with upstream and downstream customers, and enhancing enterprise value and core competitiveness. The company built the first modern pharmaceutical logistics center in Heilongjiang Province and the largest in Northeast China in January 2011, with a storage capacity of 400000 boxes and an annual throughput capacity of 30 billion yuan. It has modern logistics functions such as equipment modernization, technological diversification, management informatization, system standardization, service specialization, and rapid response. Adopting the TMS transportation management system, the entire process control of cold chain business is at an advanced level in the same industry. The logistics center has the qualification to carry out third-party logistics business. The company also has a wholesale headquarters for organic glass, which specializes in operating glass instruments, chemical reagents, and medical devices, as well as a branch of traditional Chinese medicine, which specializes in selling authentic Chinese medicinal herbs and herbal decoction pieces. These two professional branches subdivide the marketing market, making the company's drug management structure more diversified and operating characteristics more diverse. Harbin Pharmaceutical Group Sanjing Hospital Investment Management Co., Ltd., a subsidiary of the company, has the largest specialized kidney disease hospital in Heilongjiang Province - Sanjing Kidney Disease Hospital. The hospital adheres to the development concept of "large specialty, small comprehensive" and has established the largest blood purification center in the province, as well as specialized departments such as nephrology and integrated traditional Chinese and Western medicine in nephrology. At the same time, we have established the Harbin Pharmaceutical Group World Yitang Traditional Chinese Medicine Museum, where well-known experts from across the country regularly visit and provide authentic medicinal materials. We provide personalized one-on-one traditional Chinese medicine diagnosis and treatment for various difficult and complex diseases, and establish a good image of a famous doctor, medicine, and museum in the hearts of the general public.In the future development process, the company will adopt the overall development strategy of "deeply cultivating Longjiang, based in Northeast China, moving towards the whole country, and looking internationally", fully leveraging the advantages of the company's scale operation, brand operation, and chain operation, improving internal management and operational efficiency, and creating a more professional and creative workforce. On the basis of stabilizing the leading position in the region, we strive to achieve better and faster development, and strive to build Renmin Tongtai Pharmaceutical Co., Ltd. into a leading drug distribution enterprise in the country, repay society with good development results, and contribute to the development of China's pharmaceutical industry and health cause. |
| Headquarter | Harbin |
| Establish Date | 2/19/1994 |
| Listed Code | 600829.SH |
| Listed Date | 2/24/1994 |
| Chairman | Lin Ren. |
| CEO | Zhu Weidong. |
| Website | www.hyrmtt.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
